Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | CASP3 | P42574 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CASP6 | P55212 | 1/20 | 1.00 |
| ▸ | CASP8 | Q14790 | 1/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 0.95 |
| ▸ | HPGD | P15428 | 7/20 | 0.95 |
| ▸ | RAB9A | P51151 | 5/20 | 0.95 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.95 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.95 |
| ▸ | RELA | Q04206 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912737 | 0.97 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1KMT2ACASP3MEN1 | |
| SCHEMBL914037 | 0.87 | SMN1; SMN2 (0.77) | SMN1; SMN2ALDH1A1KMT2ACASP3MEN1 | |
| SCHEMBL914016 | 0.85 | SMN1; SMN2 (0.77) | SMN1; SMN2ALDH1A1KMT2ACASP3MEN1 | |
| SCHEMBL914213 | 0.85 | SMN1; SMN2 (0.77) | SMN1; SMN2ALDH1A1KMT2ACASP3MEN1 | |
| SCHEMBL3916315 | 0.84 | SMN1; SMN2 (0.76) | SMN1; SMN2ALDH1A1KMT2ACASP3MEN1 | |
| SCHEMBL914596 | 0.83 | MAPT (0.77) | SMN1; SMN2ALDH1A1KMT2ACASP3MEN1 | |
| SCHEMBL913965 | 0.82 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1KMT2ACASP3MEN1 | |
| SCHEMBL914357 | 0.81 | MAPT (0.74) | SMN1; SMN2ALDH1A1KMT2ACASP3MEN1 | |
| SCHEMBL3368748 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1KMT2ACASP3MEN1 | |
| SCHEMBL914110 | 0.81 | SMN1; SMN2 (0.95) | SMN1; SMN2ALDH1A1KMT2ACASP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | claimed |
| EP-1631295-B1 | USE OF CONDENSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | AREXIS AB (SE) | 2010-03-03 | — | — | EP | claimed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | claimed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | claimed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | claimed |
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| EP-1631295-B1 | USE OF CONDENSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | AREXIS AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | SMN1; SMN2 3806/4885ALDH1A1 584/4885KMT2A 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.